iiinova — where your digital self keeps evolving

Reposted by Mario Palma

Harvard Molecular Metabolism @met-hsph.bsky.social · 05/11/2025

Melanoma cells that spread to lymph nodes depend on FSP1 to survive, revealing a new metabolic vulnerability. New study in Nature by @mariopalma.bsky.social @ubellackerlab.bsky.social and colleagues shows that blocking FSP1 triggers ferroptosis and suppresses tumor growth in lymph node metastases.

nature.com

Lymph node environment drives FSP1 targetability in metastasizing melanoma - Nature

Targeting FSP1 in lymph nodes has considerable potential for blocking melanoma progression.

184

Mario Palma @mariopalma.bsky.social · 05/11/2025

Excited to share my postdoctoral work, out today in Nature! www.nature.com/articles/s41... We discovered that melanoma cells in lymph nodes gain a targetable FSP1 dependency that limits melanoma progression.

nature.com

Lymph node environment drives FSP1 targetability in metastasizing melanoma - Nature

Targeting FSP1 in lymph nodes has considerable potential for blocking melanoma progression.

3166

Reposted by Mario Palma

Ubellacker Lab @ubellackerlab.bsky.social · 05/08/2025

Join me in Boston October 6th for a 1-day conference on #mappingbiology to transform #cancertherapeutics. Register by September 25th to benefit from the complimentary (free) admission! Topics, speakers, and talk opportunities here: abcam.me/mappingbiolo... @abcamofficial.bsky.social

074

Reposted by Mario Palma

Ubellacker Lab @ubellackerlab.bsky.social · 07/05/2025

Our team (hsph.harvard.edu/research/ube...) is excited to have contributed to the intranodal in vivo testing of the remarkable new compound, Fentomycin-1. Congrats to team Rodriguez et al. for the implications of this work in targeting ferroptosis in cancer. Check it out here!

3207

Reposted by Mario Palma

Harvard T.H. Chan School of Public Health @hsph.harvard.edu · 23/04/2025

For more than 100 years, Harvard Chan School has worked to build a world where everyone can thrive. Our discoveries and solutions have improved life for millions of people around the globe. And we’re expanding that impact every day.

17619

Reposted by Mario Palma

Ubellacker Lab @ubellackerlab.bsky.social · 18/04/2025

A reminder that for next month’s BCDI in place of our regular discussion, we encourage you to attend the Cutter Distinguished Lecture @met-hsph.bsky.social by the great Scott Dixon! See you there: Monday May 12, 2025, Kresge Building at HSPH, G1 auditorium, 12:00-1:00pm

096

Reposted by Mario Palma

Ubellacker Lab @ubellackerlab.bsky.social · 16/04/2025

Short on time wrangling research hurdles or just life in general? @mariopalma.bsky.social and @mariesabatier.bsky.social have you covered with this focused spotlight on Ueda et al.’s work in Nature Cell Biology on oxidative niches and cancer cell dissemination. Spotlight article here: rb.gy/zi8wj9

rb.gy

Hotspots of escape: Oxidative niches prime tumor cell dissemination

Abstract. The balance between reactive oxygen species (ROS) and antioxidant defenses plays a critical role in tumor development, progression, and response to therapy. However, the detection of ROS in ...

052

Reposted by Mario Palma

Marie Sabatier @mariesabatier.bsky.social · 15/04/2025

🌟 Excited to share our latest spotlight! 🌟 Co-wrote with @mariopalma.bsky.social and Jessalyn @ubellackerlab.bsky.social, highlighting Ueda et al.'s study on oxidative niches driving immune evasion in tumors. Check out our spotlight article here: rb.gy/zi8wj9 Ueda et al., 2025: rb.gy/674im7

094

Reposted by Mario Palma

Alex Toker @alextoker.bsky.social · 26/11/2024

Great news for AKT inhibitors! Capivasertib in combo with abiraterone and ADT improves progression free survival in PTEN deficient prostate cancer! Anticipating approval for this combo, coming off the approval of capi in ER+be breast cancer. Good work AZ! www.onclive.com/view/capivas...

onclive.com

Capivasertib Plus Abiraterone/ADT Improves rPFS in PTEN-Deficient mHSPC

Capivasertib plus abiraterone and ADT improved rPFS in PTEN-deficient metastatic hormone-sensitive prostate cancer.

0313